Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
Find out how the #MaybeBaby project is supporting young people in the UK and Ireland living with #arthritis and #psoriasis to plan their futures today. https://t.co/r63gorBo0M https://t.co/TYBOmwp69V
— UCB News (@ucb_news) 19.08.2019 -
What do patients with chronic diseases want most? Our study found 75% of their unmet needs are related to emotional rather than medical issues #InspiredByPatients #DrivenByScience #PatientExperience https://t.co/pysAxsfY7b https://t.co/xLyXqJieVP
— UCB News (@ucb_news) 19.08.2019 -
We're working hard to ensure our operations are #carbonneutral by 2030. Find out how in our Green Strategy ????#sustainability #InspiredByPatients #DrivenByScience https://t.co/6WEtqwh9AV https://t.co/8DWHAtG9U1
— UCB News (@ucb_news) 16.08.2019
